Halozyme Therapeutics Company Profile (NASDAQ:HALO)

About Halozyme Therapeutics

Halozyme Therapeutics logoHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: HALO
  • CUSIP: 40637H10
Key Metrics:
  • Previous Close: $9.82
  • 50 Day Moving Average: $9.70
  • 200 Day Moving Average: $9.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.64
  • P/E Growth: 0.00
  • Market Cap: $1.26B
  • Outstanding Shares: 127,958,000
  • Beta: 2.1
Additional Links:
Companies Related to Halozyme Therapeutics:

Analyst Ratings

Consensus Ratings for Halozyme Therapeutics (NASDAQ:HALO) (?)
Ratings Breakdown: 1 Sell Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $15.63 (59.11% upside)

Analysts' Ratings History for Halozyme Therapeutics (NASDAQ:HALO)
Show:
DateFirmActionRatingPrice TargetDetails
6/23/2016Piper Jaffray Cos.Reiterated RatingOverweight$15.00View Rating Details
6/8/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/6/2016Canaccord GenuityReiterated RatingBuy$11.00View Rating Details
5/10/2016Jefferies GroupReiterated RatingSell$6.75View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$22.00 -> $20.00View Rating Details
2/24/2016Barclays PLCLower Price TargetOverweight$27.00 -> $16.00View Rating Details
11/18/2015Citigroup Inc.Initiated CoverageBuy$25.00View Rating Details
6/22/2015JPMorgan Chase & Co.Boost Price TargetOverweight$20.00 -> $25.00View Rating Details
6/1/2015MLV & Co.Reiterated RatingBuy$20.00View Rating Details
4/20/2015BMO Capital MarketsSet Price TargetBuy$26.00View Rating Details
(Data available from 8/29/2014 forward)

Earnings

Earnings History for Halozyme Therapeutics (NASDAQ:HALO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/9/2016Q216($0.27)($0.21)$29.94 million$33.30 millionViewN/AView Earnings Details
5/9/2016Q116($0.20)($0.16)$29.65 million$42.50 millionViewN/AView Earnings Details
2/29/2016Q415($0.08)$0.03$37.06 million$52.20 millionViewListenView Earnings Details
11/9/2015Q315($0.16)($0.19)$24.01 million$20.80 millionViewN/AView Earnings Details
8/10/2015Q215($0.09)$0.02$24.84 million$43.40 millionViewListenView Earnings Details
5/11/2015Q115($0.13)($0.12)$19.40 million$18.70 millionViewListenView Earnings Details
3/2/2015Q414($0.07)($0.04)$25.60 million$30.38 millionViewN/AView Earnings Details
11/10/2014Q314($0.14)($0.16)$16.50 million$14.60 millionViewN/AView Earnings Details
8/11/2014Q214($0.14)($0.13)$13.71 million$18.40 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)($0.22)$13.37 million$12.00 millionViewN/AView Earnings Details
2/27/2014Q413($0.17)($0.19)$21.80 million$12.50 millionViewN/AView Earnings Details
11/8/2013Q313($0.15)($0.17)$14.62 million$16.00 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.13)($0.13)$11.29 million$14.50 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.15)($0.17)$7.05 million$11.83 millionViewN/AView Earnings Details
2/25/2013Q4 2012($0.16)($0.04)$7.32 million$21.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.13)($0.18)$6.09 million$5.33 millionViewN/AView Earnings Details
8/6/2012($0.15)($0.13)ViewN/AView Earnings Details
5/7/2012($0.11)$0.14ViewN/AView Earnings Details
3/9/2012($0.16)($0.18)ViewN/AView Earnings Details
11/7/2011($0.03)$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Halozyme Therapeutics (NASDAQ:HALO)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-0.59 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.20)($0.17)($0.19)
Q2 20161($0.28)($0.28)($0.28)
Q3 20161($0.24)($0.24)($0.24)
Q4 20161($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Halozyme Therapeutics (NASDAQ:HALO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/20/2015Laurie StelzerCFOBuy10,000$17.24$172,400.00View SEC Filing  
6/18/2015Kenneth J KelleyDirectorSell20,000$21.00$420,000.00View SEC Filing  
9/16/2014David A RamsayCFOBuy25,000$8.90$222,500.00View SEC Filing  
9/16/2014Helen TorleyCEOBuy50,000$8.92$446,000.00View SEC Filing  
8/19/2014John Stuart PattonDirectorSell75,000$9.96$747,000.00View SEC Filing  
5/15/2014Robert EnglerDirectorSell126,700$7.56$957,852.00View SEC Filing  
9/16/2013John Stuart PattonDirectorSell75,000$9.13$684,750.00View SEC Filing  
8/19/2013H. Michael ShepardVPSell10,000$7.11$71,100.00View SEC Filing  
8/14/2013Kathryn FalbergDirectorBuy100,000$6.82$682,000.00View SEC Filing  
11/29/2012Robert EnglerDirectorBuy15,000$5.57$83,550.00View SEC Filing  
11/14/2012James P ShafferVPBuy20,000$5.22$104,400.00View SEC Filing  
11/13/2012Kathryn E FalbergDirectorBuy50,000$5.21$260,500.00View SEC Filing  
8/27/2012Kenneth J KelleyDirectorBuy20,000$5.70$114,000.00View SEC Filing  
8/13/2012Gregory Ian FrostCEOBuy2,000$5.50$11,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Halozyme Therapeutics (NASDAQ:HALO)
DateHeadline
News IconRatings & Crowd Appeal on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Post News (NASDAQ:HALO)
www.kentuckypostnews.com - August 23 at 5:31 PM
prnewswire.com logoResearch Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and ... - PR Newswire (press release) (NASDAQ:HALO)
www.prnewswire.com - August 23 at 5:31 PM
News IconResearch Report Coverage on Biotech Stocks -- Halozyme Therapeutics, Achillion Pharma, Aegerion Pharma and Chimerix (NASDAQ:HALO)
www.kswo.com - August 23 at 9:45 AM
News IconThe Key Numbers To Watch From Halozyme Therapeutics, Inc. (NASDAQ:HALO)'s Earnings - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - August 19 at 8:18 AM
finance.yahoo.com logoHALOZYME THERAPEUTICS INC Financials (NASDAQ:HALO)
finance.yahoo.com - August 18 at 5:23 PM
News IconTrading the Biotech News: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - August 18 at 8:22 AM
capitalcube.com logoETF’s with exposure to Halozyme Therapeutics, Inc. : August 15, 2016 (NASDAQ:HALO)
www.capitalcube.com - August 15 at 5:34 PM
News IconHalozyme Therapeutics Increases Estimate for Yearly Net Revenue (NASDAQ:HALO)
sdbj.com - August 14 at 5:14 PM
News IconHalozyme Increases Estimate for Yearly Net Revenue (NASDAQ:HALO)
sdbj.com - August 12 at 5:26 PM
capitalcube.com logoHalozyme Therapeutics, Inc. :HALO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:HALO)
www.capitalcube.com - August 12 at 5:26 PM
News Icon8-K: HALOZYME THERAPEUTICS INC (NASDAQ:HALO)
www.traderplanet.com - August 10 at 5:40 PM
istreetwire.com logoStocks Alert: Brookdale Senior Living (BKD), Halozyme Therapeutics (HALO), Yelp (YELP) - iStreetWire (NASDAQ:HALO)
istreetwire.com - August 10 at 12:49 PM
nasdaq.com logoEarnings Reaction History: Halozyme Therapeutics Inc., 37.5% Follow-Through Indicator, 5.4% Sensitive - Nasdaq (NASDAQ:HALO)
www.nasdaq.com - August 9 at 9:44 PM
sg.finance.yahoo.com logoHalozyme Therapeutics reports 2Q loss (NASDAQ:HALO)
sg.finance.yahoo.com - August 9 at 9:44 PM
finance.yahoo.com logoHalozyme Reports Second Quarter 2016 Financial Results (NASDAQ:HALO)
finance.yahoo.com - August 9 at 4:09 PM
biz.yahoo.com logoQ2 2016 Halozyme Therapeutics Inc Earnings Release - After Market Close (NASDAQ:HALO)
biz.yahoo.com - August 9 at 8:19 AM
News IconSecurities Analyst Recommendations: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Southwest Airlines Co. (NYSE ... - TWN (NASDAQ:HALO)
thewellesleysnews.com - August 6 at 8:15 AM
fortune.com logoStocks With Notable Analysts Assessments: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Triumph Group Inc (NYSE ... - Review Fortune (NASDAQ:HALO)
reviewfortune.com - August 5 at 5:31 PM
biz.yahoo.com logoNektar Therapeutics Earnings Call (Q2 2016) (NASDAQ:HALO)
biz.yahoo.com - August 3 at 5:42 PM
fortune.com logoNoteworthy Analyst Evaluations of Stocks: Halozyme Therapeutics ... - Review Fortune (NASDAQ:HALO)
reviewfortune.com - August 1 at 10:05 AM
sbwire.com logoNew Market Research Report: Contact Dermatitis Global Clinical Trials Review, H1, 2016 (NASDAQ:HALO)
www.sbwire.com - July 29 at 12:31 PM
sbwire.com logoAlpha 1-Antitrypsin Deficiency Treatment Market: Competitive Overview (NASDAQ:HALO)
www.sbwire.com - July 28 at 4:11 PM
fortune.com logoHalozyme Therapeutics, Inc. (NASDAQ:HALO) Earns Consensus ... - Review Fortune (NASDAQ:HALO)
reviewfortune.com - July 27 at 5:37 PM
fortune.com logoHalozyme Therapeutics, Inc. (NASDAQ:HALO) at $9.24: How much higher it can go - Review Fortune (NASDAQ:HALO)
reviewfortune.com - July 27 at 8:07 AM
reuters.com logoBRIEF-Halozyme Therapeutics says Eisai and Halozyme initiate Phase 1b/2 clinical trial - Reuters (NASDAQ:HALO)
www.reuters.com - July 27 at 8:07 AM
streetupdates.com logoAnalysts Suggestion Alert: Express Scripts Holding Company (NASDAQ:ESRX) , Halozyme Therapeutics, Inc ... - Street Updates (NASDAQ:HALO)
www.streetupdates.com - July 27 at 8:07 AM
News IconBlazing Stocks Calls Bulls- Tobira Therapeutics (NASDAQ:TBRA), Halozyme Therapeutics (NASDAQ:HALO), Alnylam ... - Seneca Globe (NASDAQ:HALO)
www.senecaglobe.com - July 26 at 5:34 PM
smarteranalyst.com logoStock Update (NASDAQ:HALO): Eisai And Halozyme Therapeutics, Inc. Initiate Phase 1b/2 Clinical Trial With First ... - Smarter Analyst (NASDAQ:HALO)
www.smarteranalyst.com - July 26 at 5:34 PM
publicnow.com logoEisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 (NASDAQ:HALO)
www.publicnow.com - July 26 at 9:18 AM
streetinsider.com logoHalozyme Therapeutics (HALO) Resumes Patient Enrollment, Dosing in PEGPH20 Trial (NASDAQ:HALO)
www.streetinsider.com - July 25 at 5:25 PM
News Icon2 Biotech Stocks News And Price Trends: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Juno Therapeutics Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - July 25 at 9:58 AM
publicnow.com logoHalozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA (NASDAQ:HALO)
www.publicnow.com - July 25 at 9:18 AM
fortune.com logoAnalyst Views That Are Worth Watching: Halozyme Therapeutics, Inc. (NASDAQ:HALO), NCI Building Systems Inc ... - Review Fortune (NASDAQ:HALO)
reviewfortune.com - July 24 at 9:46 AM
News IconA Reversal for Halozyme Therapeutics, Inc. Is Not Near. The Stock Rises Again - Consumer Eagle (NASDAQ:HALO)
www.consumereagle.com - July 22 at 8:18 AM
News IconActive biotech company shares in the news: Halozyme Therapeutics (NASDAQ:HALO), BioMarin Pharmaceutical ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - July 22 at 8:18 AM
News IconPrice Target Review: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle (NASDAQ:HALO)
www.newsoracle.com - July 22 at 8:18 AM
fortune.com logoLatest Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price Suggests Stock Is Worth $14.54/Share - Review Fortune (NASDAQ:HALO)
reviewfortune.com - July 22 at 8:18 AM
capitalcube.com logoHalozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : July 21, 2016 (NASDAQ:HALO)
www.capitalcube.com - July 21 at 8:14 AM
News IconIncreased Stock Volatility Watch: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Engelwood Daily (NASDAQ:HALO)
www.engelwooddaily.com - July 20 at 9:40 PM
equities.com logoHalozyme Therapeutics Inc. (HALO) Jumps 6.66% on July 20 - Equities.com (NASDAQ:HALO)
www.equities.com - July 20 at 9:40 PM
News IconHalozyme Therapeutics, Inc.'s Trend Up, Especially After Today's Strong Session - Consumer Eagle (NASDAQ:HALO)
www.consumereagle.com - July 20 at 3:18 PM
capitalcube.com logoETF’s with exposure to Halozyme Therapeutics, Inc. : July 20, 2016 (NASDAQ:HALO)
www.capitalcube.com - July 20 at 12:31 PM
News IconEquity Roundup: Stock Performance Focus on Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph (NASDAQ:HALO)
presstelegraph.com - July 20 at 8:15 AM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Halozyme Therapeutics, Inc. (NASDAQ:HALO) - TGP (NASDAQ:HALO)
telanaganapress.com - July 19 at 11:30 AM
news.cmlviz.com logoHalozyme Therapeutics Inc versus MiMedx Group Inc Head to Head Compare - CML News (NASDAQ:HALO)
news.cmlviz.com - July 19 at 11:30 AM
News IconIntraday Active Biotech Stocks News: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Amicus Therapeutics, Inc ... - The Voice Registrar (NASDAQ:HALO)
voiceregistrar.com - July 19 at 11:30 AM
News IconShare Performance Summary for: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Press Telegraph (NASDAQ:HALO)
presstelegraph.com - July 18 at 5:34 PM
News IconTrending Analyst Recommended Stock: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - News Oracle (NASDAQ:HALO)
www.newsoracle.com - July 18 at 5:34 PM
News IconColon Cancer Pipeline Market 2016 Review Report Covering Therapeutics Development (NASDAQ:HALO)
www.prnewswire.co.in - July 18 at 10:34 AM
News IconShares Experiencing a Downtrend: Halozyme Therapeutics, Inc. (NASDAQ:HALO) - TGP (NASDAQ:HALO)
telanaganapress.com - July 16 at 5:08 PM

Social

Halozyme Therapeutics (NASDAQ:HALO) Chart for Monday, August, 29, 2016


Last Updated on 8/29/2016 by MarketBeat.com Staff